The additive manufacturing sector continues to show near-limitless potential. Innovations have taken 3D printers from creating customized figurines all the way to printing entire neighborhoods, ...
Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 5.86% on an annualized basis producing an average annual return of 17.7%. Currently, Vertex Pharmaceuticals has a ...
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
Handelsbanken Fonder AB reduced its stake in Vertex Pharmaceuticals by 28.1% in Q4, selling 115,479 shares. The fund now owns ...
Vertex Pharmaceuticals Incorporated Investors: [email protected] Susie Lisa, CFA: +1 617-341-6108 or Miroslava Minkova: +1 617-341-6135 Media: [email protected] or International: +44 20 3204 ...
RAD Security, a San Francisco-based provider of security for cloud-focused infrastructure, raised $14 million in Series A ...
Right to work is one of four different pieces of legislation that would change collective bargaining laws for Ohio's public ...
A young Peninsula drugmaker won regulatory approval Friday for a rare-disease drug picked up in a deal two years ago.
Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback